Meds & supplements › Zilucoplan
Medicine · Complement Inhibitor
ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
ZILBRYSQ is contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection.
Pharmacy Prior to Dispensing
Store ZILBRYSQ prefilled syringes refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton until dispensing. Do not freeze.
Storage for Patients or Caregivers After Dispensing
Storage conditions after dispensing by pharmacist are summarized in Table 4:
sofidex [Internet]. Daloreum; c2026. Zilucoplan; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/zilucoplan
sofidex. (2026, August 3). Zilucoplan. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/zilucoplan
Zilucoplan. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/zilucoplan
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.